These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 3510778)

  • 1. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and regional blood flow response to piroximone (MDL 19,205) in dogs with congestive heart failure: a comparison with dobutamine.
    Petein M; Heppner B; Bache RJ; Cohn JN; Pierpont GL
    J Pharmacol Exp Ther; 1987 Jun; 241(3):956-60. PubMed ID: 3598911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute clinical benefits of a new inotropic agent AR-L 115 BS after i.v. and oral administration.
    el Allaf D; D'Orio V; Cremers S; Carlier J
    G Ital Cardiol; 1984 Oct; 14(10):830-4. PubMed ID: 6519393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dose-response relation of intravenous enoximone in congestive cardiac insufficiency].
    Lellouche D; Delorme G; Merlet P; Dubois-Randé JL; Duval AM; Tarral A; Bourdarias JP; Vernant P
    Arch Mal Coeur Vaiss; 1988 Sep; 81(9):1107-13. PubMed ID: 2973777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
    Monrad ES; Baim DS; Smith HS; Lanoue AS; Silverman KJ; Gervino EV; Grossman W
    Circulation; 1986 Mar; 73(3 Pt 2):III205-12. PubMed ID: 3510776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
    Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
    J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enoximone: hemodynamic effect in patients with cardiac insufficiency].
    de Langenhagen B; Bouchoucha H; Scholl JM; Hennetier G; Benacerraf A; Achard F; Bock F
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():19-25. PubMed ID: 2147830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute hemodynamic effects of piroximone i.v. in patients with severe heart failure].
    Scholz M; Kneissl GD; Winkelmann BW; Grohe G; Klittich P; Bussmann WD
    Z Kardiol; 1995 Oct; 84(10):827-33. PubMed ID: 7502570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term therapy with oral piroximone on resting hemodynamics, peak aerobic capacity, and the anaerobic threshold in patients with heart failure.
    Nemanich JW; Shurman AJ; Rossen JD; Kremser C; Davis F; Rajfer SI
    J Cardiovasc Pharmacol; 1987 Nov; 10(5):580-8. PubMed ID: 2447409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure.
    Petein M; Levine TB; Cohn JN
    J Am Coll Cardiol; 1984 Aug; 4(2):364-71. PubMed ID: 6736478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
    Varriale P; Ramaprasad S
    Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic therapy of severe heart failure with enoximone.
    Gilfrich HJ; Witzke-Gross J; Römer A
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S75-7. PubMed ID: 2480490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response.
    Uretsky BF; Seecof RM; Reddy PS
    Can J Cardiol; 1986; 2(2):80-5. PubMed ID: 3085906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.
    Kereiakes D; Chatterjee K; Parmley WW; Atherton B; Curran D; Kereiakes A; Spangenberg R
    J Am Coll Cardiol; 1984 Nov; 4(5):884-9. PubMed ID: 6238076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response.
    Uretsky BF; Generalovich T; Verbalis JG; Valdes AM; Reddy PS
    J Am Coll Cardiol; 1985 Jun; 5(6):1414-21. PubMed ID: 3158689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure.
    Nakano T; Morimoto Y; Kakuta Y; Konishi T; Kodera T; Kanamaru M; Takezawa H
    Arzneimittelforschung; 1986 Dec; 36(12):1829-34. PubMed ID: 3551968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
    Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
    Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the acute effect of AR-L 115 BS, a new positive-inotropic agent in patients with exercise-induced heart failure.
    Drexler H; Wollschläger H; Löllgen H; Just H
    Arzneimittelforschung; 1981; 31(1a):259-62. PubMed ID: 7195237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.